On November 6, Iovance Biotherapeutics, Inc. fell 8.22% in Regular Trading, trading at $7.95 per share, with turnover of $85.81 million.
The key catalyst was a post-earnings pullback after the company reported third-quarter results above expectations but only reiterated full-year product revenue guidance of $410 million to $420 million, without a further increase.
For the September quarter, Iovance Biotherapeutics, Inc. posted a loss of $0.05 per share, improved from a $0.25 loss a year earlier and better than consensus expectations for a $0.08 to $0.09 loss. Revenue rose to $121.5 million from $67.5 million a year earlier, ahead of expectations near $116 million. However, after previously lifting its full-year outlook in late September from $350 million-$370 million to $410 million-$420 million, the company maintained that range this time. That appears to have tempered incremental expectations despite the earnings beat.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments